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Abstract: Importance: Women experience worse ischemic and bleeding outcomes after percutaneous
coronary intervention (PCI). Objectives: To assess the association of sex with patient outcomes at 2 years
after contemporary PCI and with the efficacy and safety of 2 antiplatelet strategies. Design, Setting,
and Analysis: This study is a prespecified subgroup analysis of the investigator-initiated, prospective,
randomized GLOBAL LEADERS study evaluating 2 strategies of antiplatelet therapy after PCI in an
unselected population including 130 secondary/tertiary care hospitals in different countries. The main
study enrolled 15 991 unselected patients undergoing PCI between July 2013 and November 2015. Patients
had an outpatient clinic visit at 30 days and 3, 6, 12, 18, and 24 months after the index procedure. Data
were analyzed between January 1, 2019, and March 31, 2019. Interventions: Eligible patients were
randomized to either the experimental or reference antiplatelet strategy. Experimental strategy consisted
of 1 month of dual antiplatelet therapy (DAPT) followed by 23 months of ticagrelor monotherapy, while
the reference strategy comprised of 12 months of DAPT followed by 12 months of aspirin monotherapy.
Main Outcomes and Measures: The primary efficacy end point was the composite of all-cause mortality
and new Q-wave myocardial infarction at 2 years. The secondary safety end point was Bleeding Academic
Research Consortium type 3 or 5 bleeding. Results: Of the 15 968 patients included in this study, 3714
(23.3%) were women. The risk of the primary end point at 2 years was similar between women and men
(adjusted hazard ratio [HR], 1.00; 95% CI, 0.83-1.20). Compared with men, women had higher risk of
Bleeding Academic Research Consortium type 3 or 5 bleeding (adjusted HR, 1.32; 95% CI, 1.04-1.67) and
hemorrhagic stroke at 2 years (adjusted HR, 4.76; 95% CI, 1.92-11.81). At 2 years, there was no between-
sex difference in the efficacy and safety of the 2 antiplatelet strategies. At 1 year, compared with DAPT,
ticagrelor monotherapy was associated with a lower risk of bleeding in men (HR, 0.72; 95% CI, 0.53-0.98)
but not in women (HR, 1.23; 95% CI, 0.80-1.89; P for interaction = .045). Conclusions and Relevance:
Compared with men, women experienced a higher risk of bleeding and hemorrhagic stroke after PCI. The
effect of 2 antiplatelet strategies on death and Q-wave myocardial infarction following PCI did not differ
between the sexes at 2 years. Trial Registration: ClinicalTrials.gov identifier: NCT01813435.
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IMPORTANCE Women experience worse ischemic and bleeding outcomes after percutaneous
coronary intervention (PCI).
OBJECTIVES To assess the association of sex with patient outcomes at 2 years after
contemporary PCI and with the efficacy and safety of 2 antiplatelet strategies.
DESIGN, SETTING, AND ANALYSIS This study is a prespecified subgroup analysis of the
investigator-initiated, prospective, randomized GLOBAL LEADERS study evaluating 2
strategies of antiplatelet therapy after PCI in an unselected population including 130
secondary/tertiary care hospitals in different countries. Themain study enrolled 15 991
unselected patients undergoing PCI between July 2013 and November 2015. Patients had an
outpatient clinic visit at 30 days and 3, 6, 12, 18, and 24months after the index procedure.
Data were analyzed between January 1, 2019, andMarch 31, 2019.
INTERVENTIONS Eligible patients were randomized to either the experimental or reference
antiplatelet strategy. Experimental strategy consisted of 1 month of dual antiplatelet therapy
(DAPT) followed by 23months of ticagrelor monotherapy, while the reference strategy
comprised of 12 months of DAPT followed by 12 months of aspirin monotherapy.
MAIN OUTCOMES ANDMEASURES The primary efficacy end point was the composite of
all-cause mortality and newQ-wavemyocardial infarction at 2 years. The secondary safety
end point was Bleeding Academic Research Consortium type 3 or 5 bleeding.
RESULTS Of the 15 968 patients included in this study, 3714 (23.3%) were women. The risk of
the primary end point at 2 years was similar between women andmen (adjusted hazard ratio
[HR], 1.00; 95% CI, 0.83-1.20). Compared with men, women had higher risk of Bleeding
Academic Research Consortium type 3 or 5 bleeding (adjusted HR, 1.32; 95% CI, 1.04-1.67)
and hemorrhagic stroke at 2 years (adjusted HR, 4.76; 95% CI, 1.92-11.81). At 2 years, there
was no between-sex difference in the efficacy and safety of the 2 antiplatelet strategies. At 1
year, compared with DAPT, ticagrelor monotherapy was associated with a lower risk of
bleeding in men (HR, 0.72; 95% CI, 0.53-0.98) but not in women (HR, 1.23; 95% CI,
0.80-1.89; P for interaction = .045).
CONCLUSIONS AND RELEVANCE Comparedwithmen, women experienced a higher risk of
bleeding and hemorrhagic stroke after PCI. The effect of 2 antiplatelet strategies on death
and Q-wavemyocardial infarction following PCI did not differ between the sexes at 2 years.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01813435
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T
here are sex-based differences in the pathophysiology,
clinical presentation, and prognosis of coronary artery
disease (CAD).1,2 Invitro studies andsmall clinical stud-
ies have shown higher platelet activity, higher propensity to
thrombosis, andmore bleeding in women.3,4 The short-term
and long-termoutcomesofCADareusuallybetter inmen than
women.5
Regardless of sex, percutaneous coronary intervention
(PCI)hasbeenestablishedasaneffective treatment inCADwith
improvedoutcomes,which are comparable between sexes,6,7
attributable to theuseofsecond-generationdrug-elutingstents
(DES), imaging-guided and physiology-guided revasculariza-
tion, and potent P2Y12 inhibitors.8,9 Potent P2Y12 inhibitors
increase the risk of bleeding, and the optimal strategy of an-
tiplatelet therapy after PCI is still a matter of debate.10 Nota-
bly,cessationofantiplatelet therapy ismorecommoninwomen
thanmen, and being awoman has been identified as an inde-
pendent predictor for bleeding after PCI.11
In the GLOBAL LEADERS study, ticagrelor monotherapy
following 1-month dual antiplatelet therapy (DAPT) with as-
pirin was safe but not superior to conventional DAPT in re-
ducing the composite primary end point of all-cause mortal-
ity or core laboratory-adjudicated new Q-wave myocardial
infarction (MI) in all-comer patients undergoing PCI.12 Con-
sidering that the ischemic andbleeding risk ofwomenunder-
going PCI may differ frommen, it follows that the safety and
efficacy of long-term ticagrelor monotherapy after PCI may
differ between the sexes. Therefore,we aimed to compare the
2-year outcomes between women and men undergoing con-
temporary PCI and to assess the association of sex with the
efficacy and safety of antiplatelet strategy in the GLOBAL
LEADERS study.
Method
Study Design and Patient Population
This study is a prespecified subgroup analysis of the GLOBAL
LEADERS study. The GLOBAL LEADERS study was an inves-
tigator-initiated, prospective, randomized,multicenter,mul-
ticontinental, open-label trial designed toevaluate2antiplate-
let therapystrategies afterPCIusinguniformlybivalirudinand
biolimusA9–eluting stents (Biomatrix) in an all-comers popu-
lationwithno restriction regarding clinical presentation, com-
plexityof the lesions, ornumberof stentsused.12Patientswho
neededoralanticoagulationtherapyafterPCI,hadknownovert
major bleeding, were planned to undergo surgery within 12
monthsof PCI, or had severehepatic impairmentwerenot eli-
gible for the study.The full inclusionandexclusion criteria are
in the eMethods in Supplement 1. In the experimental strat-
egy, patients receivedaspirin, 75 to 100mg,oncedaily in com-
bination with ticagrelor, 90 mg, twice daily for 1 month; fol-
lowed by ticagrelor, 90 mg, twice daily alone for 23 months
(irrespectiveof theclinicalpresentation). In the referencestrat-
egy, patients received aspirin, 75 to 100mg, daily in combina-
tionwith either clopidogrel, 75mg, oncedaily inpatientswith
stable CAD or ticagrelor, 90 mg, twice daily in patients with
acute coronary syndrome (ACS) for 1 year; followed by aspi-
rin, 75 to 100mg, oncedaily alone for the following 12months
(from12 to24months after PCI). TheGLOBALLEADERSstudy
was approved by the institutional review board at each par-
ticipating institution. All patients provided written informed
consent. The study compliedwith theDeclaration ofHelsinki
and Good Clinical Practice. An independent data and safety
monitoring committee oversaw the safety of all patients. The
formal trial protocols can be found in Supplement 2.
Themain studyenrolled 15991patientsbetweenJuly2013
toNovember 2015 (eFigure 1 in Supplement 1). Because 23pa-
tientswithdrewconsent and requesteddatadeletion fromthe
database, a total of 15 968 patients remained in the study. Pa-
tients had an outpatient clinic visit at 30 days and 3, 6, 12, 18,
and 24months after the index procedure. Electrocardiogram
(ECG)wasobtainedatdischarge,3-monthfollow-up,and2-year
follow-upandduring follow-up if therewere suspected ische-
mic events or repeated revascularization. All ECGs were ana-
lyzed at the core laboratory (Cardialysis) by technicians who
were blinded to the treatment assignments.
Study End Points
The primary end point of the present study was the compos-
ite of all-cause mortality and new Q-wave MI within 2 years
after the index procedure. The survival status of the patients
lost to follow-upor thosewhowithdrew their consentwasob-
tained through public civil registry. More than 99.95% of the
vital status at 2 yearswere available in the study.12Minnesota
classification was used to define the new Q-wave MI, which
was centrally adjudicated by an independent ECG core labo-
ratory. The secondary safety end point was investigator-
reportedBleedingAcademicResearchConsortium(BARC) type
3or 5bleeding.13Additional secondaryendpointswere thepa-
tient-oriented composite end points (POCE) and net adverse
clinical events (NACE). Patient oriented composite endpoints
were defined as all-causemortality, any stroke (ischemic and
hemorrhagic), any MI including periprocedural or spontane-
ouswith ST-segment elevationmyocardial infarction or non–
ST-segment elevation myocardial infarction, and any revas-
cularization (re-PCI or coronary artery bypass graft surgery
[CABG] in target or nontarget vessel).14 Net adverse clinical
events were defined as POCE plus BARC type 3 or 5 bleeding.
The composite end points were analyzed according to time-
to-first-event analysis. Other end points included individual
Key Points
Question What is the association of sex with patient outcomes
after percutaneous coronary intervention?
Findings In this prespecified subgroup analysis of the GLOBAL
LEADERS randomized clinical trial, there was no between-sex
difference in the risk of 2-year all-cause mortality or newQ-wave
myocardial infarction. The risks of bleeding and hemorrhagic
stroke in womenwere higher than in men, and compared with
dual antiplatelet therapy, ticagrelor monotherapy was associated
with lower risk of bleeding at 1 year in men but not in women.
Meaning The effect of antiplatelet strategy on bleeding at 1 year
may be different between the sexes.
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component of composite end point and definite stent throm-
bosis according to Academic Research Consortium (ARC)
definition.15
Statistical Analysis
All the analyses were performed on the intention-to-treat
population. Continuous variables are expressed as mean and
standard deviation and were compared using independent t
test. Categorical variables are presented as counts and per-
centage and were compared using χ2 test. Lesion data were
analyzed using mixed-effects models to account for multiple
lesions treated within patients. Outcomes were analyzed
based on the time-to-first-event analyses in which the
repeated events were disregarded. Kaplan-Meier method was
used to estimate the cumulative rates of events, and log-rank
test was performed to examine the differences between
groups. The association of sex with the outcomes was
assessed in the unadjusted and adjusted Cox proportional
hazards model. The covariables in the adjusted model
included age, diabetes, renal impairment, presentation of
ACS, prior MI, peripheral vascular disease, chronic obstruc-
tive pulmonary disease, and history of CABG, which were
Table 1. Baseline Clinical and Angiographic Characteristics According to Sex
Characteristic
No./Total No. (%)
P ValueMen (n = 12 254) Women (n = 3714)
Baseline clinical characteristics
Age, mean (SD), y 63.69 (10.22) 67.35 (10.09) <.001
BMI, mean (SD) 28.17 (4.30) 28.25 (5.44) .34
Type 2 diabetes 2972/12 247 (24.27) 1066/3710 (28.73) <.001
Insulin-dependent diabetes 828/12 220 (6.78) 395/3701 (10.67) <.001
Hypertension 8791/12 212 (71.99) 2924/3702 (78.98) <.001
Hypercholesterolemia 8241/11 876 (69.39) 2527/3589 (70.41) .25
Current smoker 3338/12 254 (27.24) 831/3714 (22.37) <.001
Peripheral vascular disease 799/12 144 (6.58) 206/3678 (5.60) .04
Chronic obstructive pulmonary disease 618/12 198 (5.07) 203/3698 (5.49) .33
Previous major bleeding 70/12 241 (0.57) 28/3706 (0.76) .26
Impaired renal functiona 1348/12 187 (11.06) 823/3696 (22.27) <.001
Previous stroke 306/12 235 (2.50) 115/3710 (3.10) .05
Previous myocardial infarction 3009/12 216 (24.63) 701/3706 (18.92) <.001
Previous percutaneous coronary intervention 4196/12 243 (34.27) 1025/3711 (27.62) <.001
Previous coronary artery bypass grafting 781/12 246 (6.38) 162/3709 (4.37) <.001
Clinical presentation
Stable coronary artery disease 6491/12 254 (52.97) 1990/3714 (53.58) .53
Unstable angina 1493/12 254 (12.18) 529/3714 (14.24) .001
Non–ST-elevation myocardial infarction 2637/12 254 (21.52) 736/3714 (19.82) .03
ST-elevation myocardial infarction 1633/12 254 (13.33) 459/3714 (12.36) .13
Baseline angiographic characteristics
Index PCI attempted, No. 12 187 3696 NA
No. of lesions treated at index PCI per patient,
mean (SD)
1.33 (0.62) 1.28 (0.57) <.001
Lesion treated at index PCI
1 lesion 8952/12 136 (73.76) 2853/3682 (77.49)
<.0012 lesions 2518/12 136 (20.75) 669/3682 (18.17)
3 or more lesions 666/12 136 (5.49) 160/3682 (4.35)
Lesion levelb
No. of lesion 16 140 4701 NA
Vessel treated
Left main coronary artery 306/16 140 (1.90) 81/4701 (1.72)
.44
Left anterior descending artery 6599/16 140 (40.89) 2067/4701 (43.97)
Left circumflex artery 4051/16 140 (25.10) 1026/4701 (21.83)
Right coronary artery 5005/16 140 (31.01) 1485/4701 (31.59)
Bypass graft 179/16 140 (1.11) 42/4701 (0.89)
No. of stent per lesion, mean (SD) 1.19 (0.53) 1.19 (0.54) .70
Biomatrix stent used 15 038/15 896 (94.60) 4377/4628 (94.58) .99
Mean stent length, mean (SD), mm 24.99 (14.01) 24.20 (13.80) .001
Mean stent diameter, mean (SD), mm 3.01 (0.47) 2.93 (0.45) <.001
Direct stenting 5076/15 896 (31.93) 1608/4628 (34.75) <.001
Bifurcation PCI 1960/16 140 (12.14) 556/4701 (11.83) .94
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms




a Estimated glomerular filtration rate
of creatinine clearance of less than
60mL/min per 1.73 m2 based on the
Modification of Diet in Renal
Disease Formula.
bCalculated per lesion and analyzed
with general or generalized linear
mixed-effects models with a
random effect for patients to
account for multiple lesions treated
within patients.
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selected based on prior knowledge of the association of these
covariables with the outcomes.16 Hazard ratios (HRs) and
95% confidence intervals were calculated.
Theeffectofexperimentalvs referencestrategyontheout-
comeswas assessed separately in women andmen in the un-
adjustedCoxmodel. Thedifference in the treatment effect be-
tween experimental vs reference strategy inwomen andmen
was assessed in the Coxmodel with the inclusion of main ef-
fect terms (sex and treatment strategy) and interaction term
(sex × treatment strategy) for the outcome of interest.
Landmark analyses at 1 year were performed in accor-
dance to the planned discontinuation of P2Y12 receptor in-
hibitor in the reference group. A 2-sided P value less than .05
was considered statistically significant. All analyseswereper-
formed in R, version 3.4.2 (the R Foundation).
Results
Baseline Clinical and Angiographic Characteristics
Of 15 968 patients enrolled in the GLOBAL LEADERS study
between July 2013 and November 2015, 12 254 (76.7%) were
men, and 3714 (23.3%) were women. Compared with men,
women were older and had higher prevalence of diabetes,
hypertension, and impaired renal function. Women were
more likely to be nonsmokers, had lower prevalence of prior
MI, and less likely to have had previous treatment with PCI
and CABG (Table 1). The proportion of patients presenting
with stable CAD were similar between men and women.
Compared with men, women were more likely to present
with unstable angina and non–ST-segment elevation myo-
cardial infarction. Women had a lower number of lesions
treated at the index procedure than men (Table 1). Mean
stent length and mean stent diameter were lower in women
than in men. Other angiographic characteristics were similar
between both sexes.
Clinical Outcomes According to Sex
At2years, theprimaryendpointoccurred in176of3714women
(4.75%) and in477of 12254men (3.90%) (unadjustedHR, 1.23;
95% CI, 1.03-1.46; Figure 1). After adjustment for baseline
confounders, the risk of primary end point was no longer dif-
ferentbetween thesexes (adjustedHR, 1.00;95%CI,0.83-1.20).
Theriskof thesecondarysafetyendpoint (BARC3or5bleeding)









and eTable 2 in Supplement 1).
The higher rate of BARC 3 or 5 bleeding and hemorrhagic
stroke in womenwasmainly observed in the period between
the indexprocedureand1year (BARC3or5bleeding:85of3714
women[2.32%]vs168of 12254men[1.39%];adjustedHR,1.36;
95% CI, 1.04-1.79; hemorrhagic stroke: 9 of 3714 women
[0.25%] vs 6 of 12 254 men [0.05%]; adjusted HR, 4.99; 95%
CI, 1.72-14.47) (eTable 3 in Supplement 1). From1 to 2 years af-
ter PCI, the rate of BARC 3 or 5 bleeding, hemorrhagic stroke,
andotheroutcomeswerenotdifferentbetweensexes (eTable4
in Supplement 1).
Association of SexWith Antiplatelet Strategy
The effect of experimental vs reference strategy on primary
end point at 2 years was not different between the sexes (HR
Figure 1. Association of SexWith Clinical Outcomes at 2 Years After PCI








(n = 12 254)
Women,
No. (%)a









.98477 (3.90) 176 (4.75)All-cause mortality or new Q-wave MI 1.23 (1.03-1.46) 1.00 (0.83-1.20)
.70346 (2.83) 131 (3.53)All-cause mortality 1.26 (1.03-1.54) 0.96 (0.78-1.18)
.69139 (1.15) 47 (1.29)New Q-wave MI 1.12 (0.81-1.56) 1.07 (0.76-1.51)
.84380 (3.16) 118 (3.25)MI 1.03 (0.84-1.27) 1.02 (0.82-1.27)
Stroke
.31113 (0.94) 49 (1.35)Overall 1.45 (1.03-2.02) 1.19 (0.85-1.69)
.8597 (0.81) 34 (0.94)Ischemic 1.17 (0.79-1.73) 0.96 (0.64-1.43)
.0019 (0.08) 13 (0.36)Hemorrhagic 4.81 (2.05-11.25) 4.76 (1.92-11.81)
.751188 (9.89) 344 (9.53)Any revascularization 0.96 (0.85-1.09) 0.98 (0.87-1.11)
.70102 (0.84) 26 (0.71)Definite stent thrombosis 0.85 (0.55-1.30) 0.92 (0.59-1.42)
.02223 (1.85) 109 (2.99)BARC 3 or 5 bleeding 1.63 (1.30-2.05) 1.32 (1.04-1.67)
.721665 (13.72) 516 (14.08)Patient-oriented composite end points 1.03 (0.94-1.14) 0.98 (0.89-1.09)








.12Net adverse clinical events 1.08 (0.98-1.18) 1.01 (0.91-1.11)
BARC indicates Bleeding Academic Research Consortium; HR, hazard ratio.
a Data were analyzed using the unadjusted Kaplan-Meier method.
bAdjusted by age, diabetes, renal impairment, presentation of acute coronary
syndrome, priormyocardial infarction (MI), peripheral vascular disease, chronic
obstructive pulmonary disease, and history of coronary artery bypass grafting.
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for men, 0.85; 95% CI, 0.71-1.02; HR for women, 0.92;
95% CI, 0.69-1.24; P for interaction = .63; Figure 2). Land-
mark analyses of the primary end point at 1 year and
between 1 to 2 years showed no significant interaction
between sex and antiplatelet strategies (eFigure 2 and
eFigure 3 in Supplement 1).
No significant difference in the effect of antiplatelet strat-
egy on secondary safety end point (BARC 3 or 5 bleeding) at 2
years between the sexes was observed (HR for men, 0.85;
95% CI, 0.65-1.10; HR for women, 1.26; 95% CI, 0.87-1.84; P
for interaction = .09; Figure 2 and Figure 3). Compared with
reference strategy, the experimental strategy was associated
with a lower risk of BARC 3 or 5 bleeding at 1 year inmen (HR,
0.72; 95% CI, 0.53-0.98) but not in women (HR, 1.23; 95% CI,
0.80-1.89, P for interaction = .045) (Figure 3; eFigure 2 in
Supplement 1).
Theeffectof experimental and referenceantiplatelet strat-
egyonotheroutcomesat2years includinginvestigator-reported




(eFigures 2 and 3 in Supplement 1).
Table 2 shows the rate of adherence to antiplatelet strat-
egy at follow-upbetweenwomenandmen. Thepercentage of
men and women adhering to their treatment strategy were
similar at discharge and 1-month follow-up, whereas rates of
adherencewerehigher inmen from the 3-month follow-up to















No. (%)aOutcomes at 2 y
HRb, exp/ref
(95% CI)
All-cause mortality or new Q-wave myocardial infarction
.6091 (4.93) 85 (4.56)Women 0.92 (0.69-1.24)
.08258 (4.21) 219 (3.59)Men 0.85 (0.71-1.02)
All-cause mortality
.30Women 71 (3.84) 60 (3.22) 0.83 (0.59-1.18)
.35182 (2.97) 164 (2.68)Men 0.90 (0.73-1.12)
New Q-wave myocardial infarction 
.6922 (1.22) 25 (1.37)Women 1.12 (0.63-1.99)
.0581 (1.34) 58 (0.97)Men 0.72 (0.51-1.00)
Myocardial infarction
.8260 (3.33) 58 (3.18)Women 0.96 (0.67-1.38)
.92190 (3.15) 190 (3.17)Men 1.01 (0.83-1.23)
Stroke overall
.8625 (1.39) 24 (1.31)Women 0.95 (0.54-1.67)
.9657 (0.95) 56 (0.94)Men 0.99 (0.68-1.43)
Ischemic stroke
.71Women 18 (1.00) 16 (0.88) 0.88 (0.45-1.73)
.7950 (0.83) 47 (0.79)Men 0.95 (0.64-1.41)
Hemorrhagic stroke 
.425 (0.28) 8 (0.44)Women 1.59 (0.52-4.85)
.734 (0.07) 5 (0.08)Men 1.26 (0.34-4.70)
Any revascularization
.21182 (10.11) 162 (8.95)Women 0.87 (0.71-1.08)
.38611 (10.13) 577 (9.65)Men 0.95 (0.85-1.06)
Definite stent thrombosis
.2316 (0.88) 10 (0.55)Women 0.62 (0.28-1.36)
.5348 (0.79) 54 (0.90)Men 1.13 (0.77-1.67)
BARC 3 or 5 bleeding
.23Women 48 (2.65) 61 (3.33) 1.26 (0.87-1.84)
.22121 (2.00) 102 (1.70)Men 0.85 (0.65-1.10)
Patient-oriented composite end point
.14273 (14.94) 243 (13.23)Women 0.88 (0.74-1.04)
.25858 (14.07) 807 (13.36)Men 0.95 (0.86-1.04)
Net adverse clinical events

















934 (15.31) 868 (14.37)Men 0.93 (0.85-1.02)
BARC indicates Bleeding Academic Research Consortium; HR, hazard ratio;
RR, risk ratio.
a Data were analyzed using the unadjusted Kaplan-Meier method.
bUnadjusted hazard ratio between experimental (exp) vs reference (ref)
strategy in each sex.
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2 years. Compared with men, women had a lower rate of ad-
herence to ticagrelormonotherapyat 18monthsand24months
after PCI, while at the same time adherence to aspirin mono-
therapy was similar between sexes (eTables 5 and 6 in
Supplement 1). In patients who were allocated to ticagrelor
treatment, the rate of dyspnea within 2 years was 18.17% in
women (508 of 2796) and 14.71% in men (1370 of 9316)
(P < .001). Among patients who were not adherent to anti-
platelet strategy at 2 years, the rate of dyspnea was higher
in women than men (193 of 570 [33.9%] vs 465 of 1625
[28.6%]; P = .02).
Discussion
In thisprespecifiedsubgroupanalysisof theGLOBALLEADERS
study, the association of sex with clinical outcomes after PCI
according to2different antiplatelet strategieswas studied.The
Figure 3. Interaction Between Sex and Antiplatelet Strategy on Primary Efficacy and Secondary Safety End Point






















































































































Primary efficacy end point, 2 yB
Reference strategy
Experimental strategy
Clopidogrel + aspirin for 12 mo followed by aspirin
Ticagrelor + aspirin for 12 mo followed by aspirin
Ticagrelor monotherapy after 1-mo DAPT 
Reference strategy
Experimental strategy
Clopidogrel + aspirin for 12 mo
Ticagrelor  + aspirin for 12 mo



















































































































BARC 3 or 5 bleeding, 2 yD
Reference strategy
Experimental strategy
Clopidogrel + aspirin for 12 mo followed by aspirin
Ticagrelor + aspirin for 12 mo followed by aspirin
Ticagrelor monotherapy after 1-mo DAPT 
Reference strategy
Experimental strategy
Clopidogrel + aspirin for 12 mo
Ticagrelor + aspirin for 12 mo
Ticagrelor monotherapy after 1-mo DAPT 
The x-axis shows the categories of the patients according to sex and clinical
presentation, and the y-axis shows the unadjusted Kaplan-Meier (KM) estimate
of primary efficacy end point (all-causemortality or newQ-wavemyocardial
infarction) or secondary safety end point (BARC 3 or 5 bleeding) at 1 and 2 years
after percutaneous coronary intervention. ACS indicates acute coronary
syndrome; CAD, coronary artery disease; DAPT, dual antiplatelet therapy.
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main findings are as follows. First,womenexperienced a simi-
lar risk of ischemic events comparedwithmen at 2 years after
PCI after adjustment for confounders. Second, women had a
higher rate of hemorrhagic stroke and BARC 3 or 5 bleeding
compared with men at 2 years after PCI, with the difference
observedmainlyduringthefirstyearafterPCI.Third, therewere
no significant between-sex differences in the effect of the ex-
perimental and reference antiplatelet strategy on outcomes at
2 years after PCI. However, comparedwith reference strategy,
the experimental strategy was associated with a lower risk of
BARC 3 or 5 bleeding at 1 year in men but not in women (P for
interaction = .045).
Early studies reported that women with CAD had a
poorer prognosis than men.17 Women treated for CAD are
usually older and have higher prevalence of comorbidities
that affect the outcomes.2 After adjustment for the con-
founders, many studies have shown a comparable ischemic
risk after PCI between men and women.18-20 In addition, the
sex gap in outcomes after revascularization has been attenu-
ated by the efficacy and safety of DES, as demonstrated by
several all-comer stent trials showing similar long-term out-
comes between sexes after PCI.6,9 In this study, women were
older and had higher prevalence of diabetes, hypertension,
and impaired renal function than men, and the unadjusted
analysis shows the higher risk of primary end point and other
ischemic outcomes in women. However, the differences were
no longer evident in the adjusted models, suggesting that the
differences in ischemic risk between women and men were
attributed to confounders and not associated with sex per se.
Furthermore, it could be speculated that the sex gap may
have been diminished by contemporary PCI practice with the
use of newer-generation DES, potent antiplatelet agents, and
optimal medical therapy.
Regardless of sex, DAPT with aspirin and P2Y12 inhibitor
has been the standard of care in patients treated with DES to
prevent stent thrombosis and other ischemic events.12 In
patients with ACS, guidelines recommend potent P2Y12
inhibitors, such as ticagrelor or prasugrel, in combination
with aspirin, given that they have been shown to reduce the
risk of ischemic adverse events after revascularization.21,22
However, this benefit comes at the expense of an increased
bleeding risk.23 Several studies have shown that women
treated with antiplatelet therapy after PCI are at high risk of
bleeding, and female sex is well recognized as an indepen-
dent predictor for bleeding.11,24 However, risk scores to pre-
dict bleeding after PCI, such as the PARIS bleeding risk25 and
PRECISE DAPT score,26 did not identify any predictive value
for female sex, and sex was not subsequently included in the
risk model. Because both risk scores were developed in
populations in which potent P2Y12 inhibitors were not
widely used, it is unclear whether sex still affects the risk of
bleeding after PCI.
Thisstudyreveals thatwomenundergoingPCIareathigher
risk ofmajor bleeding andhemorrhagic stroke thanmen. This
differencepersists after adjustment for confounders, confirm-
ing that sex is an independent predictor for major bleeding
after PCI. Therefore, our findings question thepredictive abil-
ity of bleeding risk scores where sex is not included and em-
phasizes theneed forexternalvalidationofbleeding risk scores
in contemporary PCI practice.
The European Association of PCI survey in 2015 on DAPT
inclinical practice revealed that sex isoneof thevariablesphy-
siciansuse toweigh the risks of bleeding vs ischemia after PCI
with DES.27 However, a 2017 meta-analysis28 of randomized
clinical trials has shown the comparable efficacy and safety of
potentP2Y12 inhibitorsbetweensexes, suggesting that thede-
cision to use these agents should not rely on sex. Further-
more, guideline recommendations on the use of antiplatelet
therapy after PCI are independent of sex.12 However, we did
observe an interaction between sex and antiplatelet strategy
on bleeding at 1 year.
In the referencegroupof theGLOBALLEADERSstudy, the
P2Y12 inhibitor component of DAPT was dependent on clini-
cal presentation; patients with stable CAD received clopido-
grelwhile patientswithACS received ticagrelor. In the experi-
mental group, bothpatientswith stableCADandpatientswith
ACS received ticagrelor. Theobserved interactionbetweensex
and antiplatelet strategy at 1 year was primarily driven by the
experimental strategy in women with stable CAD (Figure 3).
In women with stable CAD, the rate of BARC 3 or 5 bleeding
associated with experimental strategy was almost 2 times
higher than in the reference strategy,while inmenwith stable
CAD, the rate was almost equal between the 2 strategies. Al-
though the evidence supporting routine use of potent P2Y12
inhibitors in stable CAD is lacking, off-label prescription has
been reported to be as high as 34%.29 The 2017 European So-
cietyofCardiology–focusedupdateonDAPTgaveclass IIb rec-
ommendation for the consideration of potent P2Y12 inhibitor
in patients with stable CAD undergoing PCI after taking into
account the ischemic and bleeding risk.30Our study suggests
Table 2. Adherence to Antiplatelet Strategy and Sex
Variable
No./Total No. (%)
P ValueaMen (n = 12 254) Women (n = 3714)
Discharge 11 905/12 228 (97.4) 3603/3696 (97.5) .72
Follow-up, mo
1 11 519/11 938 (96.5) 3450/3596 (95.9) .14
3 10 631/11 786 (90.2) 3136/3540 (88.6) .006
6 10 418/11 701 (89) 3023/3506 (86.2) <.001
12 10 008/11 590 (86.4) 2888/3493 (82.7) <.001
18 9782/11 400 (85.8) 2858/3420 (83.6) .001
24 9913/11 538 (85.9) 2878/3448 (83.5) <.001 a P value derived from χ2 test.
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that potent P2Y12 inhibitors should be used with caution in
women who present with stable CAD.
The lower rate of adherence to antiplatelet strategy in
women compared withmen found in this study is consistent
with data from the PARIS registry where DAPT cessation was
more common in women owing to disruption for bleeding or
discontinuation due to noncompliance.11 In the Bern PCI
registry,31 female sex was identified as an independent pre-
dictor for premature ticagrelor cessation, which was largely
owing to bleeding or dyspnea. This observation should en-
courage physicians to carefully weigh the risk and benefit of
using ticagrelor in women.
Limitations
First, the randomization in theGLOBALLEADERstudywasnot
stratifiedby sex.Hence, thenumber ofwomenenrolled in the
studywas lower thanmen, and the results are at risk for a type
II error. Second, our analyses are considered exploratory, and
statistical adjustment for multiple testing was not per-
formed. Therefore, the difference in the effect of antiplatelet
strategy on bleeding between sexes could be a play of chance
andshouldberegardedashypothesis-generating.32Finally, the
trial did not have a clinical adjudication committee for seri-
ous adverse events owing to limited financial resources. The
end points were site-reported with the exception of primary
end point: all-cause death and new Q-wave MIs assessed by
an independent ECG core laboratory. However, the trial was
monitored for consistency, and reporting of events and on-




lar between women and men. Nevertheless, women experi-
enced higher risk of bleeding and hemorrhagic stroke com-
paredwithmen.Theeffect of 2antiplatelet strategiesondeath
and Q-wave myocardial infarction following PCI did not dif-
fer between the sexes at 2 years.
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